For a heart just damaged by a blocked artery, timing matters. So does access. That is what makes a new experimental treatment ...

Good afternoon, and welcome to Niagen Bioscience Inc.'s 2025 results investor call. With us today are Niagen Bioscience Inc.'s Chief Executive Officer, Rob Fried; Chief Financial Officer, Ozan Pamir; ...

This study presents a valuable finding on the mutational order for common alterations in colorectal cancer. The evidence of in vitro growth assays comparing mutations is solid, although inclusion of ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.